CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D chief

CRISPR Therapeutics $CRSP and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG, have inked a collaboration agreement with StrideBio to develop AAV vectors for in vivo gene delivery applications. StrideBio’s task will be to develop “vectors with improved properties such as tissue specificity and reduced susceptibility to immune responses.”

→ The Oncologic Drugs Advisory Committee (ODAC) will meet on May 24 to discuss Puma’s $PBYI application for its cancer drug neratinib.

→ Cambridge, MA-based Merrimack Pharmaceuticals $MACK appointed Daryl Drummond as its new head of research. Drummond’s last post at the company was as Vice President of Discovery and Team Leader for Merrimack’s early-stage pipeline.

→ Vancouver-based Zymeworks has set terms for its looming IPO. The biotech aims to raise around $65 million by selling 4.5 million shares at $13 to $16 each. And insiders have dibs on $42 million of that, abut two-thirds of the total.

→ Brisbane, CA-based Aimmune Therapeutics named Eric Bjerkholt as Chief Financial Officer. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->